• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neuron >Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift.
【24h】

Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift.

机译：阿尔茨海默氏病中的抗abeta疗法：范式转变的需求。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Most current Alzheimer's disease (AD) therapies in advanced phases of development target amyloid beta-peptide (Abeta) production, aggregation, or accumulation. Translational models suggest that anti-Abeta therapies may be highly effective if tested as agents to prevent or delay development of the disease or as therapies for asymptomatic patients with very early signs of AD pathology. However, anti-Abeta therapeutics are currently being tested in symptomatic patients where they are likely to be much less effective or ineffective. The lack of alignment between human clinical studies and preclinical studies, together with predictions about optimal trial design based on our understanding of the initiating role of Abeta aggregates in AD, has created a treatment versus prevention dilemma. In this perspective, we discuss why it is imperative to resolve this dilemma and suggest ways for moving forward in the hopes of enhancing the development of truly effective AD therapeutics.
机译：在发展的晚期，当前的大多数阿尔茨海默氏病（AD）治疗都针对淀粉样β肽（Abeta）的产生，聚集或积累。转化模型表明，如果将抗Abeta疗法作为预防或延缓疾病发展的试剂，或者作为具有非常早期AD病理征象的无症状患者的疗法进行测试，则抗Abeta疗法可能非常有效。但是，目前正在有症状的患者中对抗Abeta治疗药物进行测试，这些患者的疗效或无效性可能要低得多。人类临床研究与临床前研究之间缺乏一致性，以及基于我们对Abe​​ta聚集体在AD中起初作用的理解而对最佳试验设计的预测，造成了治疗与预防的难题。从这个角度出发，我们讨论了为什么必须解决这个难题，并提出了前进的道路，以期希望增强真正有效的AD治疗药物的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号